Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Revelation Biosciences (NASDAQ:REVB) has issued a reminder for their upcoming webcast and conference call scheduled for September 10th at 8:30 am Eastern Time. The event will discuss top-line data from their PRIME Phase 1b clinical trial.
Participants can join via webcast or dial in using the toll-free number 888-506-0062 (US) or +1 973-528-0011 (International) with access code 289672. The company has made available both the original data announcement and the presentation materials on their website.
Revelation Biosciences (NASDAQ:REVB) ricorda il webcast e la conference call in programma per il 10 settembre alle 8:30 (ET). Durante l'evento saranno discussi i dati principali dello studio clinico PRIME Phase 1b.
Per partecipare è possibile seguire il webcast o chiamare il numero verde 888-506-0062 (USA) oppure +1 973-528-0011 (internazionale) con il codice d'accesso 289672. Sul sito dell'azienda sono disponibili l'annuncio dei dati e le slide della presentazione.
Revelation Biosciences (NASDAQ:REVB) recuerda su webcast y conference call programados para el 10 de septiembre a las 8:30 am hora del Este. El evento tratará los datos principales del ensayo clínico PRIME Phase 1b.
Los participantes pueden unirse vía webcast o marcando el número gratuito 888-506-0062 (EE. UU.) o +1 973-528-0011 (internacional) con el código de acceso 289672. En la web de la compañía están disponibles el comunicado de datos original y el material de la presentación.
Revelation Biosciences (NASDAQ:REVB)는 동부 시간 기준 9월 10일 오전 8:30에 예정된 웨비캐스트 및 컨퍼런스 콜을 재안내합니다. 이번 행사에서는 PRIME Phase 1b 임상시험의 주요 결과가 논의됩니다.
참가자는 웨비캐스트로 시청하거나 미국 무료전화 888-506-0062 또는 국제전화 +1 973-528-0011에 접속 코드 289672를 입력해 전화로 참여할 수 있습니다. 회사 웹사이트에 원문 데이터 발표문과 발표 자료가 게재되어 있습니다.
Revelation Biosciences (NASDAQ:REVB) rappelle son webcast et sa conférence téléphonique prévus le 10 septembre à 8h30, heure de l'Est. L'événement présentera les données principales de l'essai clinique PRIME Phase 1b.
Les participants peuvent se joindre via le webcast ou appeler le numéro gratuit 888-506-0062 (États-Unis) ou +1 973-528-0011 (international) avec le code d'accès 289672. L'annonce initiale des données et les supports de présentation sont disponibles sur le site de la société.
Revelation Biosciences (NASDAQ:REVB) erinnert an den bevorstehenden Webcast und die Telefonkonferenz am 10. September um 8:30 Uhr Eastern Time. In der Veranstaltung werden die Topline-Daten der PRIME Phase 1b-Studie besprochen.
Teilnehmer können per Webcast teilnehmen oder über die gebührenfreie Nummer 888-506-0062 (USA) bzw. +1 973-528-0011 (international) mit Zugangs-Code 289672 einwählen. Auf der Unternehmenswebsite sind die ursprüngliche Datenmitteilung und die Präsentationsunterlagen verfügbar.
- None.
- None.
SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th webcast at 8:30 am Eastern Time, which can be accessed here or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use the participant access code 289672. We look forward to reviewing the data with you tomorrow morning.
A copy of the original press release announcing data can be found here.
A copy of the presentation to be reviewed can be found here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and the treatment of chronic kidney disease.
For more information on Revelation, please visit https://www.revbiosciences.com.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
When is Revelation Biosciences (REVB) hosting its PRIME Phase 1b data webcast?
How can investors join Revelation Biosciences' PRIME Phase 1b data conference call?
What will be discussed in REVB's upcoming conference call?
Where can investors find materials for Revelation Biosciences' PRIME Phase 1b presentation?
